Safety and Efficacy of Anti-TNFα Treatment in Crohn's Disease Patients with Abdominal Abscesses.
L Ibanez-Samaniego, F Diaz-Fontenla… - Hepato …, 2015 - europepmc.org
L Ibanez-Samaniego, F Diaz-Fontenla, MB José, C Acosta, I Barcelo, V Flores…
Hepato-gastroenterology, 2015•europepmc.orgResults 12 patients were finally included in the study. All were treated with broad-spectrum
antibiotic and biological therapy (anti-TNF); indication of anti-TNFα therapy was moderate to
severe activity of CD in all of them. Percutaneous drainage of the abscess was performed in
7 of the 12 patients. No complications were observed during a mean follow-up of 37, 8 (16-
71) months, including abscess volume increase, enterocutaneous fistula, soft tissue
infections, bacteraemia, or need for emergency surgery. Conclusions In addition to …
antibiotic and biological therapy (anti-TNF); indication of anti-TNFα therapy was moderate to
severe activity of CD in all of them. Percutaneous drainage of the abscess was performed in
7 of the 12 patients. No complications were observed during a mean follow-up of 37, 8 (16-
71) months, including abscess volume increase, enterocutaneous fistula, soft tissue
infections, bacteraemia, or need for emergency surgery. Conclusions In addition to …
Results
12 patients were finally included in the study. All were treated with broad-spectrum antibiotic and biological therapy (anti-TNF); indication of anti-TNFα therapy was moderate to severe activity of CD in all of them. Percutaneous drainage of the abscess was performed in 7 of the 12 patients. No complications were observed during a mean follow-up of 37, 8 (16-71) months, including abscess volume increase, enterocutaneous fistula, soft tissue infections, bacteraemia, or need for emergency surgery.
Conclusions
In addition to conventional treatment, the use of anti-TNFα therapy in Crohn's disease patients with abdominal abscesses seems to be safe. Usefulness of this approach has to be validated in larger cohorts.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果